Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technetium-labeled myocardial perfusion agents

J Heo1, A S Iskandrian

  • 1Philadelphia Heart Institute, Presbyterian Medical Center, Pennsylvania.

Cardiology Clinics
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and characterization of iodovanadinite using PdI<sub>2,</sub> an iodine source for the immobilisation of radioiodine.

RSC advances·2022
Same author

Effect of total cholesterol level variabilities on cerebrovascular disease.

European review for medical and pharmacological sciences·2022
Same author

<i>Bifidobacterium longum</i> DS0956 and <i>Lactobacillus rhamnosus</i> DS0508 culture-supernatant ameliorate obesity by inducing thermogenesis in obese-mice.

Beneficial microbes·2020
Same author

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Oncoimmunology·2019
Same author

Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas.

Neoplasma·2017
Same author

Intrahepatic Artery Pseudoaneurysm-induced Hemobilia Caused by a Plastic Biliary Stent After ABO-incompatible Living-donor Liver Transplantation: A Case Report.

Transplantation proceedings·2016
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Thallium-201 has been the standard for myocardial perfusion imaging but has limitations. New technetium-99m agents offer improved options for diagnosing coronary artery disease.

Area of Science:

  • Nuclear cardiology
  • Radiopharmaceuticals

Background:

  • Thallium-201 (Tl-201) has been the primary agent for myocardial perfusion imaging since 1975.
  • Despite its widespread use, Tl-201 presents limitations concerning photon energy, half-life, and availability.

Purpose of the Study:

  • To describe the kinetics and imaging experience with technetium-99m (Tc-99m) labeled perfusion agents.
  • To highlight the advantages of Tc-99m agents over Tl-201 for myocardial perfusion imaging.

Main Methods:

  • Review of clinical trials and imaging experience with Tc-99m sestamibi and teboroxime.
  • Comparison of pharmacokinetic and dosimetric properties of Tc-99m agents versus Tl-201.

Main Results:

  • Two Tc-99m-labeled agents, sestamibi and teboroxime, were approved in 1990.

Related Experiment Videos

  • Tc-99m agents offer potential advantages over Tl-201 for myocardial perfusion imaging.
  • Ongoing research explores additional Tc-99m-based perfusion agents.

    • Conclusions:

    • Technetium-99m-labeled agents represent a significant advancement in myocardial perfusion imaging.
    • These agents provide viable alternatives to thallium-201, addressing its limitations.
    • Further development of Tc-99m agents is expected to enhance diagnostic capabilities in coronary artery disease.